1. 2005 Guidelines for the management of hemophilia http://www.wfh.org
2. How we choose factor VIII to treat hemophilia;Mannucci;Blood,2012
3. Food and Drug Administration Draft quantitative risk assessment of vCJD risk potentially associated with the use of human plasma-derived Factor VIII manufactured under United States (US) license from plasma collected in the US 2006 http://www.fda.gov/downloads/BiologicsBloodVaccines/SafetyAvailability/BloodSafety/UCM095104.pdf
4. National Hemophilia Foundation board of Directors MASAC recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders http://www.hemophilia.org
5. Millar C vCJD and haemophilia Textbook of Hemophilia, Third Edition. Edited by Christine A. Lee, Erik E. Berntorp and W. Keith Hoots. © 2014 John Wiley & Sons, Ltd.